ID

25136

Descripción

Study ID: 100478 Clinical Study ID: 100478 Study Title: Study to show non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix™-HepB/Hiberix™ without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00290303 Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine Trade Name: Tritanrix HepB/Hiberix Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis This form contains the study conclusion form

Palabras clave

Versiones (1)
  1. 27/8/17 27/8/17 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

27 de agosto de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

GSK non-inferiority of Tritanrix Hepatitis B study conclusion NCT00290303

Inglés

GSK non-inferiority of Tritanrix Hepatitis B study conclusion NCT00290303

1 formularios  
STUDY CONCLUSION FOR MENCEVAX™ ACWY 1/5th OF A DOSE STAGE
Descripción

STUDY CONCLUSION FOR MENCEVAX™ ACWY 1/5th OF A DOSE STAGE

Alias
UMLS CUI-1
C1707478
Did the subject experience any Serious Adverse Event during the study period ?
Descripción

Serious Adverse Event

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1519255
Specify total number of SAE´s:
Descripción

number of SAE

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0449788
UMLS CUI [1,2]
C1519255
Did any elimination criteria become applicable during the study? If Yes, please specify
Descripción

elimination criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
Did any elimination criteria become applicable during the study? If Yes, please specify
Descripción

elimination criteria

Tipo de datos

text

Alias
UMLS CUI [1]
C0680251
Was the subject withdrawn from study?
Descripción

withdrawn

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C0008976
Major reason for withdrawal
Descripción

Major reason for withdrawal

Tipo de datos

text

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C0392360
Who made the decision:
Descripción

Decision:

Tipo de datos

integer

Alias
UMLS CUI [1]
C0679006
Date of last contact
Descripción

Date of last contact

Tipo de datos

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1705415
Was the subject in good condition at date of last contact
Descripción

Was the subject in good condition at date of last contact

Tipo de datos

integer

Alias
UMLS CUI [1]
C0348080
Investigators signature
Descripción

Investigators signature

Tipo de datos

text

Alias
UMLS CUI [1]
C2346576
Printed Investigators name
Descripción

Printed Investigators name

Tipo de datos

text

Alias
UMLS CUI [1]
C2826892
Date
Descripción

Date

Tipo de datos

date

Alias
UMLS CUI [1]
C0011008
Volver a la parte superior de la página

Similar models

GSK non-inferiority of Tritanrix Hepatitis B study conclusion NCT00290303

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
STUDY CONCLUSION FOR MENCEVAX™ ACWY 1/5th OF A DOSE STAGE
C1707478 (UMLS CUI-1)
Serious Adverse Event
Item
Did the subject experience any Serious Adverse Event during the study period ?
boolean
C1519255 (UMLS CUI [1])
number of SAE
Item
Specify total number of SAE´s:
text
C0449788 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
elimination criteria
Item
Did any elimination criteria become applicable during the study? If Yes, please specify
boolean
C0680251 (UMLS CUI [1])
elimination criteria
Item
Did any elimination criteria become applicable during the study? If Yes, please specify
text
C0680251 (UMLS CUI [1])
withdrawn
Item
Was the subject withdrawn from study?
boolean
C2349954 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
Item
Major reason for withdrawal
text
C2349954 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Major reason for withdrawal
Code List
Major reason for withdrawal
CL Item
Non Serious adverse event (AEX)
CL Item
Consent withdrawal not due to an adverse event (CWS)
CL Item
Lost to follow up (LFU)
CL Item
Migrated moved from the study area (MIG)
CL Item
Other (OTH)
CL Item
Protocol violation (PTV)
CL Item
Serious adverse event (SAE)
Item
Who made the decision:
integer
C0679006 (UMLS CUI [1])
Decision:
Code List
Who made the decision:
CL Item
Investigator (1)
CL Item
Parents/Guardians (2)
Date of last contact
Item
Date of last contact
date
C0011008 (UMLS CUI [1,1])
C1705415 (UMLS CUI [1,2])
Item
Was the subject in good condition at date of last contact
integer
C0348080 (UMLS CUI [1])
Was the subject in good condition at date of last contact
Code List
Was the subject in good condition at date of last contact
CL Item
No, Please give details in Adverse Events section. (1)
CL Item
Yes (2)
Investigators signature
Item
Investigators signature
text
C2346576 (UMLS CUI [1])
Printed Investigators name
Item
Printed Investigators name
text
C2826892 (UMLS CUI [1])
Date
Item
Date
date
C0011008 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial